At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
In Brief
A Phase 2 clinical trial evaluating Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, and 19 other interventions for Acute Lymphoblastic Leukemia and Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1. Completed, enrolled 66 participants across 101 sites.
Detailed Summary
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Undergo peripheral blood allogeneic HCT
Undergo peripheral blood autologous HCT
Given IV
Given IV
Given PO
Given IV
Given PO or IV
Given IV
Given SC
Given IV
Undergo peripheral blood autologous or allogeneic HCT
Correlative studies
Given IV or PO
Given IV
Given PO
Given IT, IV, or PO
Given SC
Correlative studies
Given IV or PO
Given IV